The global bacteriophages therapy market stands at a crossroads under the shadow of the COVID-19 crisis. The crisis-driven halt of manufacturing facilities and suspension of shipments has resulted in a reduced reliance on international suppliers of API (active pharmaceutical ingredients) products. Biopharmaceutical firms are establishing their wholly-owned production capabilities to meet the local drug demand, which, in turn, is widening the scope of the market.
0